The British pharmaceutical company, GlaxoSmithKline (GSK), has completed the acquisition of the American company Tesaro, which manufactures onco drugs. The deal value exceeded $5 billion. The information was announced in December 2018. GlaxoSmithKline believes that the deal will strengthen the pharmaceutical business and expand the prospects for cancer treatment. Tesaro President, Mary Lynn Hadley, expects that the purchase of GSK will help extend the life of many cancer patients and continue the company's development and commercialization initiatives.
SoftBank cancels $3 billion deal for additional WeWork Shares31.03.2020
E-firm Alibaba to buy 10% shares in Chinese courier Yunda: sources20.03.2020
First round of QE sees Australia central bank buy $2.9 billion bonds18.03.2020
Airlines' cash drawers emptied, virus causes $157 billion loss from share values